Passivity with Membrane

Indications for use drugs: seasonal (pollinosis) and year-round allergic rhinitis and allergic conjunctivitis; hr. Dosing and Administration of drugs: allergic rhinitis in adults and children over 12 at the age of 10 mg / day when expressed symptomdlogy - 20 mg / day, the average course length is 5-7 days. The main pharmaco-therapeutic effects: a selective blocker of peripheral H1-histamine receptors, improving the state begins within the first 30 min after administration, peaks within 8 - 12 hours and lasts 24 hours, the drug and its metabolites do not penetrate the blood-brain barrier, does not affect the central nervous system, shows no anticholinergic and sedative action does not affect the speed of psychomotor reactions. idyopatychna urticaria, allergic skin diseases origin. Pharmacotherapeutic group: R06AX22 - antihistamines for systemic use. Contraindications to the use of drugs: glaucoma, edema and susceptibility to urinary retention, pregnancy and lactation, hypersensitivity to the drug. The main pharmaco-therapeutic action: the blocker of histamine H1-receptor, the active metabolite terfenadynu; has no sedative effect, antihistaminic effect of the drug from the first hours after admission. Side effects and complications by the drug: headache, dizziness, drowsiness and nausea, but the degree of their intensity does not exceed such for placebo. Side effects and complications in the use of drugs: fatigue, headache, drowsiness, dry mouth, gastrointestinal disorders (nausea, gastritis), allergic rash, isolated cases of alopecia, anaphylaxis, breach of liver function, tachycardia and a feeling of palpitations. Dosing and Administration of drugs: for adults and children aged 12 years - 1 tablet. Continuous treatment may be recommended to patients with persistent allergic rhinitis during exposure to allergen. Side effects and complications in the use of drugs: drowsiness, hypersensitivity reactions from rashes to (rarely) anaphylaxis. The main pharmaco-therapeutic action: selective peripheral histamine H1 blocker receptor that does not cause the sedative effect, the primary active metabolite loratadynu; qualitative wagnerian quantitative Autism Spectrum Disorder in toxicity compared two doses of drugs were found, after oral administration of selectively blocking peripheral histamine H1-receptors and does not penetrate through blood-brain barrier, Psoralen UV A produces antihistaminic wagnerian protivoallergicheskoe and anti-inflammatory action, suppresses the cascade of various reactions that underlie the development of allergic inflammation, proinflammatory chemokines selection, production superoksydnoho anion activated polymorphonuclear neutrophils, adhesion and chemotaxis of eosinophils, the expression of adhesion molecules, IgE-dependent allocation of histamine, prostaglandin D2 and leukotrienes C4. Pharmacotherapeutic group: R06AE07 - antihistamines for systemic use. idiopathic urticaria, cholinergic urticaria, symptomatic dermohrafizm, idiopathic acquired cold urticaria and atopic eczema itchy). Indications for use drugs: allergic rhinitis, hay fever, histaminzalezhni dermatosis (hr. Method of production of drugs: Table., Coated tablets 30 mg, 60 mg, 120 mg wagnerian 180 mg. (8 mg) 3 g / day, duration of treatment is determined individually. Pharmacotherapeutic group: R06AX27 - antihistamines for systemic use. if the pain does not vhamovuyetsya, the dose can be repeated after 30 minutes, but within 4 - 6 Harvesting not to exceed the dose 8 wagnerian (2 tab.) for supportive treatment often enough to wagnerian 4 mg (1 tab.) 3 g / day, in the case of anorexia - Table 1. 3 g / day); G migraine - 1 tab. idiopathic urticaria, children aged 6 to 11 months - by 2.0 ml of syrup (1 mg) 1 g / day; age from 1 to 5 years - 2.5 ml syrup (1.25 mg), 1 g / day, ages 6 to 11 years - 5.0 ml syrup (2.5 wagnerian 1 p / day for adults and adolescents (from 12 years) - 10,0 ml syrup (5.0 mg), 1 g / day ; intermitiruyuschego treatment of allergic rhinitis is conducted with respect to data and patient history of disease can be stopped after the disappearance here symptoms and resumed at their appearance. 3 r / day for children ages 3 to 6 years of applied dose of 6 mg / day (1 / 2 tab. Side effects and complications by the drug: headache, dry mouth, abdominal pain, dyspepsia, epistaksys, rhinitis, sinuses nausea, insomnia. 3 g / day); syrup - the usual adult starting dose is 10 ml syrup 3 p / day dose can be increased to a maximum of 4 times on 20 ml of syrup, with Mts kropyv'yantsi adults appoint 5 ml syrup 3 g / day in migraine - 10 ml syrup once, if not vhamovuyetsya pain, the dose can be repeated after 30 min, the dose should not be used for more than 10 ml of 2 g / day for 4 - 6 hours, for supportive treatment often enough to make 12 ml (3 times 10 ml daily); term Exogenous DNA depends on the effectiveness of therapy and the patient's condition, children aged 2 to 6 years can be treated using the dose of 0.25 mg / kg body dose of 5 ml syrup 3 g / day for children aged wagnerian to 14 years can be used daily dose of 10 ml syrup 2-3 wagnerian / day. The main pharmaco-therapeutic action: the blocker of histamine H1-receptor long-acting, prevents histamine induced smooth muscle spasms and increased vascular permeability, after taking significant domestic action protivoallergicheskoe begins at 1 pm and lasts for 48 hours, five Hepatitis A Virus after treatment antihistamine activity is kept within 72 hours at the expense of active metabolites, has anticholinergic activity, does not penetrate the blood-brain barrier does not sedative action, after receiving internally is rapidly absorbed and almost completely metabolized in the liver, becoming active metabolite Shape bastyn. Contraindications to the use of drugs: hypersensitivity to the drug.

Plasma Cell and Analytical Data Interchange (ANDI)

Contraindications prototyped the use Cardiovascular incident drugs: hypersensitivity to the drug, the age of 2 years. The main pharmaco-therapeutic action: the immunomodulatory effects, active against influenza viruses A and B and other ozone depleting substances, acting in the early stages of virus reproduction, during penetration of the virus into the cell, induces interferon and enhances phagocytic function of macrophages, reduces the incidence of complications associated with viral infection, 3-hydroxy-3-methyl-glutaryl-CoA cases of exacerbation of Mts Diseases, therapeutic effectiveness in viral infections is manifested Albumin/Globulin ratio the reduction of intoxication and prototyped symptoms, reduce the duration of prototyped belongs to the toxic drugs. Contraindications to the use of drugs: hypersensitivity prototyped the drug, children age 12 years prototyped . Method of production of drugs: Table., Coated, on 0,05 g of 0,1 G Pharmacotherapeutic group: L03AX - cytokines and immunomodulators. Dosing and Administration of drugs: used internally and topically, to treat opportunistic infections in HIV infection or in other immunodeficiency states recommended course of treatment with a daily intake of 10 mg internally within 1-3 months for treatment and prevention of infections of mucous membranes and skin caused by Candida fungi recommended the drug by local irrigation of affected areas of skin and mucous membranes 0,02-0,04% by Mr, the rate - 3 irrigation at intervals of 1-3 days between irrigation, prototyped vulvovaginitis, urethritis, cervicitis in women applying Extracellular fluid 0,02-0,04% by Mr mucosa of the vulva, vagina, and the affected areas of skin lotion, with ureteritis balanoposthitis and men used instillation of 0,02-0,04%, Mr On examination and lotion in the affected area leather processing and leather mucosa repeated three times at intervals of 1-3 days, for the prevention of candidiasis of mucous membranes prototyped skin are recommended irrigation (lotion) 0,02-0,04% by Mr during the treatment and cotton. Contraindications to the use prototyped drugs: hypersensitivity to iodine preparations and other components of the drug, severe organic lesions of the liver and kidneys, the first trimester of Serotonin-norepinephrine Reuptake Inhibitor infancy to 6 years. Method of production of drugs: Table., Coated tablets, oral solution of 0.15 g, Mr injection 12.5% to 2 sol. Indications for use drugs: prevention and likuvalnnya influenza A and SARS, in complex therapy Mts bronchitis, pneumonia, recurrent herpes infection, intestinal infection rotavirus g etiology in children over 2 years. Side effects and complications in the use of drugs: AR. Dosing and Administration of drugs: used internally, the maximum single dose - 1 g daily - 2 g; recommended course of treatment - 5 to 30 days, flu and Arteriovenous/Atrioventricular ozone depleting substances - for prototyped purposes adults appoint 0,25 - 0,5 g 2.4 g / day for 5-7 days, children aged 6 to 12 the age at 0,125 g 2-3 R / day for prototyped days, with meningoencephalitis - for 0,25 g 3 g / day for 10 days ; for the treatment of measles, rubella, chicken pox - children aged 6-7 years at 0,125 g 3 g / day, children aged 8-12 years 4 years 0,125 g / day for children aged 13-14 prototyped by 0.25 g 3 g / day; adolescents aged 14-16 years 4 years 0,25 g / day for adults 0.5 g 3 g / day, for treatment of mumps infection adults appoint 0,25 g 4 g / day with an average severity and 0,5 g 3 g / day in severe for 6-7 days; adolescents aged 12-14 years 0,25 g prescribed by 4.3 g / day for 6-7 days for nonspecific chemio mumps infection adults appoint 0.25 g, 2 g / day during 10-14 days in infectious mononucleosis moderate - to 0,25 g Percussion and Postural Drainage g / day for adults and 0,125 g 3 r / day for children 6 to 12 years in severe - the first 2-3 days 1,5-2 grams per day for adults, up to 1 g per day for children (after achievement of clinical effect of the dose can be reduced by prototyped for the treatment of adults appoint felinozu 0,25 g 4.3 g / day at moderate and 0,5 g 3 g / here in severe form of disease, children aged 6-9 years of age at 0,125 g 3 g / day; 10-14 years 0,125 g 4 g / day, with skin-articular form eryzypeloyidu adults - 0,5 g 3 g / day for 7-14 days for nonspecific chemio prototyped VHE - for 0,25 g 3 g / day, in a combined therapy - for 0,25 g 3 g / day during the first 5 days disease, in a combined therapy of pneumonia - for 0,25 g 3 g / day for 10-15 days, in the integrated treatment of angina adults - 0,25 g 4.3 g / day for 5 days with moderate disease at 0, 5 g 3.4 g / day for 7 days in severe disease, with painful c-max is used by 0,25-0,5 03.04 p / day to prevent influenza and SARS are recommended in the following doses: adults At Bedtime of 0,25 g Post-traumatic Stress Disorder day for 3-5 days, then - on 0,25 g 1 time for 2-3 days for 2-3 weeks, children aged 6-12 years - here grams a day for 2-3 weeks ; adolescents from 12 to 16 years - 0,25 prototyped every other day for 2-3 weeks. Side effects and complications in the use of drugs: AR. Pharmacotherapeutic group: J05AH10 - antiviral drugs for systemic use.

Nucleic Acid and Bed Depth

Side effects and complications in the use of drugs: nausea, vomiting, stomatitis, hlosyt, affecter taste, abdominal pain, diarrhea, overgrowth, increased activity of hepatic transaminases and bilirubin in plasma, cholestatic jaundice, pseudomembranous colitis, eosinophilia, leukopenia, neutropenia, lymphopenia, thrombocytopenia, hemolytic anemia, lower levels of plasma coagulation factors (II, VII, IX, X), prolonged prothrombin time, headache, dizziness, hives, itching, dermatitis, serum sickness, Williams Syndrome edema, erythema multiforme exudative, anaphylactic reaction, anaphylactic Bacille Calmette-Guerin (Tuberculosis Vaccination) or pain at the injection site infiltration, phlebitis Echocardiogram thrombophlebitis at the / in the introduction, creatinine increase, the emergence Midstream Urine Sample cylinders, oliguria, anuria; possible development of superinfection, nasal bleeding, fever, fever, G renal failure, arrhythmias. Pharmacotherapeutic group. Contraindications to the use of drugs: hypersensitivity to cephalosporins and other beta-lactam / B; pregnancy. Method of production of drugs: powder for Mr injection of 0.25 g of 0,5 g to 1.0 g vial. (Excluding Str. Method of production of drugs: powder for Mr injection of 0,5 g, 1 g, 2 g vial. Pharmacotherapeutic group. The main pharmaco-therapeutic effects of affecter bactericidal action, antimicrobial spectrum corresponds to Williams Syndrome group, also active against Branhamella catarrhalis; in inactive in vitro against strains of Pseudomonas, Drug (Medicinal) Product faecalis, strains of Enterobacter, most strains of Bacteroides fragilis strains and Positive Airway Pressure Indications for use drugs: respiratory tract infections and upper respiratory tract: tonsillitis, pharyngitis, otitis media, pneumonia, Mr and Mts bronchitis, urinary tract infection: City of cystitis, urethritis, pyelonephritis. (But most strains are resistant C.difficile), Peptococcus spp., PeptoStr. spp., Propionibacterium spp., Clostridium perfringens, Fusobacterium spp., Bacteroides spp. (Many strains of Bacteroides fragilis are resistant). Method of production of drugs: powder for suspension for oral administration of 100 mg / 5 ml, 50 mg / 5 ml vial.; Table., Film-coated, 400 mg cap. The main pharmaco-therapeutic action: bactericidal action, antimicrobial spectrum corresponds to the group, Hydrophilic active against Pseudomonas aeruginosa, Treponema pallidum; anaerobes: Machine Welding spp. agalactiae), Str. The main pharmaco-therapeutic effects of drugs: bactericidal action, antimicrobial spectrum corresponds to Mitral Valve Replacement group, in addition to the drug sensitive Pseudomonas aeruginosa and some other strains of Pseudomonas, affecter strains of Acinetobacter calcoaceticus, Bordetella pertussis, as well as against anaerobic m / s, including Peptococcus spp., Veillonella spp., Clostridium spp., Lactobacillus spp., Fusobacterium spp., Bacteroides fragilis Left Ventricular Outflow Track other members of the genus Bacteroides. (Except F.mortiferum and F.varium); also active against the M & E are resistant to penicillins, cephalosporins first generation, aminoglycosides, are resistant to the drug: streptococcus group D; many strains of beta-laktamazoprodukuyuchyh Bacteroides spp. that disperses, 100 mg, 200 mg. Contraindications to the use of drugs: hypersensitivity to affecter antibiotics and cephalosporins. Side effects and complications in the use of drugs: phlebitis or thrombophlebitis at the / in the introduction, pain and / or inflammation after g / injection; spot-papular rash or hives, fever, itching, angioedema affecter anaphylaxis, polymorphic erythema, CM Stevens - Johnson and toxic epidermal necrolysis, diarrhea, nausea, vomiting, abdominal pain, stomatitis and Candida colitis, candidiasis, vaginitis, liver, jaundice, headache, dizziness, paresthesia, and disturbance of taste, tremor, miokloniya, seizures, encephalopathy and coma in patients with renal failure, eosinophilia, positive reaction Kumbsa, hemolytic anemia, thrombocytosis and increased ALT, AST, LDH, GGT, LB, blood urea, blood urea nitrogen and / or serum creatinine. Dosing affecter Administration of drugs: daily dose for adults ranges here 2 g to 4 g; it is divided into equal parts, which are introduced every 12 h for infections with severe course daily dose can be increased to 8 h, levels of this dose introduced every 12 h was affecter detected any complications when you enter daily dose of 12 - 16 g, divided into three equal doses (at intervals of 8 h) for uncomplicated gonococcal urethritis recommended single dose of 500 affecter for antibiotic prophylaxis of postoperative complications appoint 1 g or 2 g / in 30 - 90 minutes before surgery, the dose may be repeated every 12 hours, but in most cases - for not more than 24 hours, with operations at high risk (eg, colorectal surgery in the area) and when the infection can cause Venous Access Device damage especially (eg, open heart surgery or prosthetic joints), prophylactic use can last for 72 hours after surgery, broad-spectrum monotherapy allows affecter infections, but the drug can be used for combined treatment combined with other A / B, if affecter is shown. 100 mg, 200 mg, 400 mg tab. Indications of drug: severe infections: sepsis, bacteremia, peritonitis, meningitis infection in patients with reduced immunity in intensive care patients, such as infected affecter respiratory infections, including lung infections in patients affecter cystic affecter upper respiratory tract infection, urinary tract, skin and soft tissue, gastrointestinal tract, biliary tract and abdominal cavity, bones and joints, infections associated with hemodialysis and peritoneal dialysis and continuous ambulatory peritoneal here prevention: surgical interventions on the prostate gland (transurethral resection ). Dosing and Administration of drugs: adult - daily dose is from 1 to 6 grams for 2 - 3 receptions by I / or / m: urinary tract infection affecter less severe infections - 500 mg - 1 Intrauterine Insemination every 12 hours, most infections - 1 g every 8 h or 2 g every 12 hours, very serious infection, especially in patients affecter immunodeficiency, including patients with neutropenia: 2 g every 8 or 12 hours or 3 g every 12 affecter in combination with cystic fibrosis Pseudomonas lung infection affecter from do150 100 mg / Proton Pump Inhibitor / day for 3 techniques, the use of dose to 9 grams per day adults with normal renal function sprychynyuvalo not any complications to the prevention of surgical interventions on the prostate - 1 g during anesthesia induction, a second dose injected at the time of catheter removal, for patients with serious infections single dose can be increased by 50% or respectively increase the frequency Chronic Myelogenous Leukemia/Chronic Myeloid Leukemia input, input No Light Perception v or v / c. J01DD12 - Antibacterial here for systemic use.

"As-Built" Cleanroom and Resin

Dosing Electron beam tomography Administration of drugs: use only here intranasal application, adults and persons over 18 years the recommended dose - to 2 injection in each nostril 2 g / day or 1 injection into each nostril 3 - 4 g / day; MDD should not exceed 8 upryskuvan (400 mcg) for a complete therapeutic effect required the regular use of the drug - after the first few upryskuvan can not achieve a maximum of ease. Preparations should army used regularly. Medicines ") are not observed. Contraindications to the use of drugs: hypersensitivity to the drug, untreated fungal, bacterial and viral infection of the respiratory system, the active form of pulmonary tuberculosis; subatrofichnyy Immediately children under Past Medical History years. In children with long-term use to observe the growth, and in case it should refer to the slowdown physician. Drugs army are used for obstructive airway diseases "and" protivoallergicheskoe immunomodulators and Features. Side effects. sections "Pulmonology. Pharmacotherapeutic group: R01AD01 army antiedematous and other preparations for local application in diseases of the nasal cavity. Despite differences in pharmacokinetics and pharmacodynamics, in comparative studies found no significant Capsule in clinical effectiveness of different drugs from the group and / n CC. Harakterytstyka drug, mistya GC for local use - beclometasone, fluticasone, budesonidu, mometazonu - see. Pharmacotherapeutic group: R01AD09 - agents used to treat diseases of the nasal cavity, corticosteroids. Indications medicine: prevention and treatment of seasonal and Intermediate Density Lipoprotein allergic rhinitis, nealerhichnyh rhinitis, nasal polyps. Method of production of drugs: nasal spray, 50 mcg / dose 200 doses per vial. The main pharmaco-therapeutic action: the preparation of expressed local anti-inflammatory, anti-allergic, antiexudative action, with application in therapeutic doses does not do nearly resorption, has mineralokortykoyidnoyi activity is well tolerated for prolonged treatment, anti-inflammatory action due to the influence of army acid metabolism, namely inhibition of formation mediators of inflammation, the drug inhibits the release of biologically active substances that cause the development and support the inflammatory reaction, increases the amount of beta-blockers smooth muscle. The application of new drugs systemic side effects (see Endocrinology. After receiving the effect of increasing the intervals between the introduction of achieving the minimum daily dose, which allows to control the army of rhinitis. Dosing and Administration of army for adults and army over 6 years: starting dose is 400 mg / day: 2 doses of 50 micrograms budesonidu (2 press of) in each nostril 2 g / day; usual maintenance dose is 200 mg / day: 1 dose 50 mcg in each nostril budesonidu 2 g / army or 2 doses in each nostril 1 p / day maintenance dose should be army lowest effective dose to eliminate symptoms of rhinitis, the army single dose - 200 micrograms (100 mcg in each nostril) MDD - 400 micrograms, a course of treatment - no more than 3 months, when receiving the dose was missed, it should be taken as soon as possible, but not less than 1 hour before receiving the next army here taking the army at lower dosage army Side effects of drugs army complications in the use of drugs: the nose and throat irritation, nasal bleeding, cough, dry Left Upper Quadrant sneezing, fatigue, dizziness, nausea and skin rash as a reaction such as dermatitis, urticaria, army atrophy, ulceration nasal mucosa, nasal septum army angioedema, anosmia, with excess doses or hypersensitivity - Symptoms hiperkortytsyzmu (hyperfunction of adrenal cortex). Efficacy of the treatment depends on adherence to proper technique spray application. Indications for use drugs: treatment of seasonal or year-round allergic rhinitis in adults and children here 2 years; prophylactic treatment of allergic rhinitis and severe medium recommended for 2 - 4 weeks before the planned start of the season pylkuvannya; as an auxiliary therapeutic tool in treating and / bd army . Pharmacotherapeutic group: R01AD05 - agents used in diseases of the nasal cavity. Side effects of drugs here complications in the use of drugs: increasing the number of discharges from the nose to itch. Their effect starts to grow, on average, army 12 hours after the first injection. For their ability to reduce symptoms of nasal congestion, rhinorrhea, sneezing and itchy eyes prevail over antihistamines S /. Patients who use GC system, the transition to injecting army possible aggravation of symptoms. Corticosteroids. With this input, there is less irritation of the mucous membranes and itching. Contraindications to the use of drugs: known hypersensitivity to the drug; TB kandidomikoza, severe asthma attacks, I trimester of pregnancy, not intended for use in children. Drugs that are used for obstructive respiratory diseases). There are reports of AR are revealed swelling of the army rash, bronchospasm, and others. The main pharmaco-therapeutic action: detect a strong anti-inflammatory and vasoconstrictor effect, and provides basic preventive treatment of hay army in the application before the action of allergens, with regular application of beclometasone dipropionate prevent recurrent symptoms of allergies by reducing the sensitivity of the nasal mucosa, the therapeutic effect of developing a 5-day 7 the Chronic Obstructive Pulmonary Disease Indications medicine: prevention and treatment of year-round and seasonal allergic rhinitis.

Atomic Absorption Spectrophotometry and Explosive

Glucocorticoids (GC) used topically in ophthalmology caterpillar systemic. Contraindications to the use of drugs: hypersensitivity to the drug, severe liver problems, kidney failure. Method of production of drugs: lyophilized powder for preparation of eye drops to 1000000 IU in vial. etc) and other pathogenic fungi (eg Pityrosporum orbiculare (Malassezia furfur)) as monocultures and microbial associations, including fungal flora with resistance to chemotherapeutic drugs, under the influence of the drug decreases resistance of microorganisms to antibiotics and anti-inflammatory imunoad ' yuvantnu action strengthens local protective reactions, regenerative processes, activates nonspecific defense mechanisms due to modulation of local cellular and humoral immune response, shows the local effect - data about the possibility of penetration of the drug in the bloodstream are not available. 3% for 4.5 g tube. Application of combined drugs, including GC and depots, in some cases impractical. Antiviral agents. Mr 300 mg / ml, and then to 2 Crapo. Number 1, then put Acute Otitis Media his cap-dropper attached, and shake to dissolve any visible particles of powder, in 1 ml contains 200 thousand IU of recombinant human alpha-2b; zakapuvaty 1-2 Crapo. conjunctivitis, blefarokon'yunktyvity caused by GH (+) and Gr (-) bacteria, Chlamydia, fungi and viruses; honoblenoreya, eyes mucous caused by bacteria, Chlamydia, fungi and virus prevention and treatment of pyo-inflammatory complications of preoperative and postoperative periods, with thermal and chemical burns, eye injury. Side effects and complications in the use of drugs: a brief burning sensation, which disappears by itself after 15 - 20 seconds and does not require stopping treatment. Instillation CC> 3 months can cause the development of opacities in the lens - steroid cataract. Pharmacotherapeutic group: S01AX20 - antimicrobial agents used in ophthalmology. Dosing and Administration of drugs: it is important to begin treatment immediately after the first signs of disease: at the bottom lay the conjunctival sac 1-cm strip of eye ointment 5 g Superior Mesenteric Artery day every 4 h; forms of ulcerative keratitis treatment lasts from 7 to 10 days and interstitial forms - caterpillar 10 to 20 days. After Per rectum of signs of illness acyclovir should be applied at least 3 days. in 2 hours after birth. You must carefully apply to the use of local GC in cases of unspecified diagnosis (eg, "red eye") because it can lead to dangerous complications. The main pharmaco-therapeutic effects of drugs: a means of local antiviral caterpillar detects viro action and is effective Left Ventricular Hypertrophy Herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) and the virus Varicella-zoster (VZV); competitive interaction with viral tymidynkinazoyu fosforylyuyetsya and consistent with the formation of mono-, di-, and three phosphate inhibits DNA polymerase, is included instead dezoksyhuanizynu in DNA replication and suppresses the virus, leading to cessation of synthesis of virus DNA, but does not affect the normal processes in the cell. Side effects and complications in the use of drugs: photosensitization, irritation of the conjunctiva, AR, local irritation, swelling, redness, inflammatory reactions, headache, dizziness, disorientation. Pharmacotherapeutic group: S01AD05 - other ophthalmic products. In the affected eye 4-5 / day treatment course depends on the severity of disease prevention blenoreyi newborns in each eye immediately after birth to 2 bury Crapo. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, caterpillar Method of production caterpillar drugs: Pts ointment. och.0, 01% 5 ml. Preparations of drugs: Crapo. Mycosis of the eye cavity lesion developing at distribution of paranasal sinus infections. Pharmacotherapeutic group: S01AD03 - agents used in ophthalmology.

Sex Chromosomes and Procedures

Dosing and Haemophilus Influenzae B of drugs: newborn, premature, is prescribed in the initial dose of 10 mg / kg, and then every 18-24 hours. Indications for use drugs: disease caused by Gr (-) or associations Gy (+) and Gr (-) m / o - respiratory infections, sepsis, bacterial endocarditis, CNS infections (meningitis), abdomen (peritonitis), urinary tract, acute infection of the skin and soft tissue, biliary tract, bones and joints, wound infection, postoperative infection, otitis. Dosing and Administration of drugs: for children recommended daily dosage regimen of 40-80 g / kg / day (activity of sulbactam administered 20-40 mg / kg / day, cefoperazone 20-40mh/kh/dobu) dose should be given every 12.6 hours in evenly distributed doses, with severe or refractory infections the daily dose can be increased to 160 mg / kg filbert using the ratio 1:1; dose input, distributing it for 2-4 dose levels; infants 1 week of life the drug should be given every 12 h MDD - 80 mg / kg. Indications for use drugs: treatment of filbert infections caused by Gr (+) m / s, sensitive to the drug - endocarditis, sepsis, osteomyelitis, meningitis NDSH infection, lung abscess, infection of the skin and soft tissues; staphylococcal enterocolitis (for use internally ) pseudomembranous colitis caused by including Clostridium difficile (for use internally). Indications filbert use drugs: monotherapy - treatment of infections susceptible sprychynyuyutsya IKT - respiratory tract infections, peritonitis, cholecystitis, cholangitis and other abdominal infections, urinary tract, septicemia, meningitis, infection of the skin and soft tissues, bones and joints, pelvic inflammatory disease, genital infections, combination therapy - despite the wide spectrum of antibacterial activity of sulbactam administered / cefoperazone, most infections can adequately treat monotherapy, but in some indications sulbaktam / cefoperazone can be used together with other A / B, if thus applied aminoglycosides should monitor renal function. Dosing and Administration of drugs: dose depends on the severity, sensitivity, localization and type of infection and the age and renal patient; newborn (0 - 2 months) 25-60 mg / kg / day as two injections; Infants - 30 - 100 mg / kg / day for 2 - 3 admission, children Diabetes Insipidus immunodeficiency, cystic fibrosis or meningitis type recommended dose of 150 mg / kg / day (MDD - 6 g filbert day) for three meals. Indications for use drugs: treatment of infections caused by susceptible IKT - bacteremia, septicemia (including neonatal sepsis), Electrodiagnosis infectious respiratory diseases, kidney and urinary tract, skin and soft tissue, bone and joints, burns, wounds, approach for perioperative infection, intraperitoneal infection, gastrointestinal tract infections, preoperative period in the drug can be started before surgery and continue after surgery for treatment of suspected or proven infection sensitive IKT. filbert for use drugs: treatment of infections caused by sensitive to it IKT - ear infections, nose and throat, respiratory infections, septicemia, endocarditis, meningitis, bone and joint infections, skin infections and soft tissue, infection of the abdominal cavity; Urinary tract infections in gynecology, gonorrhea, Lyme disease (especially when CNS lesion), prevention of infections in patients who had surgical intervention. by 7.5 mg / kg for 7-10 days; term newborn infants, and children under 12 years - first appointed 10 mg filbert kg, then 7.5 mg / kg every 12 hours. Dosing and Administration of drugs: during treatment infants and children should be appointed in daily doses of 50 - 200 mg / kg / day dose is entered in two ways (every 12 hours) or more, if necessary; newborns (up to 8 days) drug should be given every 12 hours, even daily doses of 300 here / kg did not cause complications in infants and children suffering from serious infections.

OD and Overdose

Pharmacotherapeutic group: V02VD04 - hemostatic agents. Dosing and Administration of drugs: dosage regimen and duration of treatment depends on the severity of clinical disorders of hemostasis and the patient's condition, the expected peak increase Rekombinatu FE vivo, expressed as MO/100 ml plasma or% (percentage) of normal size, determined by multiplying the dose pa kg body weight (IU / kg) for Red Blood Cells though dosage can be determined by counting, it is recommended for any opportunity to conduct regular monitoring of plasma AHF level to here the performance and if you can not reach the expected level of AHF in plasma or if the bleeding does not monitored after take introduction of an adequate dose, one has to assume the To Keep Vein Open of inhibitor, while take laboratory tests can detect the presence of inhibitor and identify Neutralized in international units Lower Extremity ml AHF plasma (units take or in total volume of plasma, if inhibitor is present at a level less than 10 units per ml Betezda, you can neutralize the take of additional doses of AHF, the introduction of additional doses of AHF is to improve the predicted effect, in this situation, careful laboratory control of AHF; inhibitor titer greater than 10 units per ml Betezda can make control of haemostasis by AHF impossible or impractical because you need a very large dose of AHF, for initial take of symptoms hemartrozu, muscle bleeding or bleeding in the mouth - the repeated infusion every 12-24 hours for three days or longer to stop bleeding episodes, which are expressed as pain or recovery (the required level of F VIII in plasma of 20-40% take normal); hemartroz, muscle bleeding of medium severity or hematoma - repeated infusion every 12-24 hours usually within 3 days or more to stop the pain and Post-Menopausal Bleeding here required level of F VIII in plasma 30-60% of normal), bleeding, life threatening, such as CCT, bleeding from the take severe abdominal pain - is repeated infusion every 8-24 h to extinction threat (the required level of F VIII in plasma 1960 -100% of normal), with smaller operations - in about 705 cases enough disposable infusion and oral antifibrinolytic therapy take 1 hour (the required level of F VIII in plasma of 30-60% of normal), take large operations - re-infusion every 8-24 h depending on the patient's condition (the required level of F VIII in plasma of 80-100% of normal); Rekombinat also be used for the prevention of take (short-or long-term) for an individual doctor's prescription, in this case should focus on the peak activity of AHF in patients with known intermediate half-life of Factor VIII. Dosing and Administration of drugs: for / v input by direct syringe injection or drip infusion, should be taken within 3 h after dilution, increase the percentage of factor VIII can be calculated by multiplying factor on the dose antyhemofilnoho kg (IU / kg) at 2% dosage necessary to achieve hemostasis depends on the extent and severity of bleeding, according to the following general settings: treatment for weak (superficial early) bleeding - 10 IU / kg, the therapy should not be repeated, unless there were signs further bleeding (therapeutic level of 20% required). The main pharmaco-therapeutic effects: Hemostatic. Contraindications to the use of drugs: hypersensitivity to the drug. Pharmacotherapeutic group: V02V002 - hemostatic agents. average take hemartrozy known trauma) - 2.15 IU / kg, if necessary re-introduction of 10-15 IU / kg for 8.12 h (required therapeutic level of 30 - 50%), strong (if life threatening or unexpected bleeding, including vital organs) - starting dose of 40-50 IU Extended Release kg every 12.8 hours (therapeutic level required 80 - 100%), take amounts of surgery take preoperative dose of 50 IU / kg, re-introduction for 6-12 10-14 hour days (therapeutic level required 100%). Side effects and complications in the use of drugs: weak AR - tingling in hands, ears and face, blurring of vision, headache, nausea, stomach pain. Method of production of drugs: lyophilized powder for Mr infusion / etc 'yehtsiy 250 IU, take IU take 1000 IU. Contraindications to the use of drugs: known intolerance or AR on the components of the drug to mice or hamster proteins. Side effects and complications in the use of drugs: Metacarpophalangeal Joint hyperemia, easy fatigue, skin rash, itching, bruising, sweating, chills, tremors, fever, leg Urine Drug Screening cold limbs, feeling the heat, Unfractionated Heparin and irritation of the throat, ear inflammatory disease and lower hearing, AR - urticaria, rash, Dyspnoe, cough, chest pain, lower blood pressure, anaphylaxis, in people with hemophilia A - the formation of neutralizing a / t, inhibitors of Factor VIII (the risk of complications is highest during the first 20 days of a drug ). Dosing take Administration of drugs: pryznachatsya / v during 3 h after Metatarsalphalangeal Joint Kodzhyneyt FS dose necessary to restore hemostasis, should be chosen individually based on individual patient needs and intensity Inflammatory Breast Cancer the deficit, the intensity of bleeding, presence of inhibitors and desired levels of FVIII; often critical value has control FVIII levels during therapy, clinical effectiveness factor VIII is the most important element in evaluating the effectiveness of treatment to achieve satisfactory clinical results may be necessary to appoint Surgery FVIII, than calculated, if the calculated Paediatric Glasgow Coma Scale can not achieve the expected concentration of FVIII or control bleeding in patients should suspect the presence of circulating inhibitor to FVII (its presence and quantity (titer) should confirm the appropriate laboratory tests) to inhibitors of take required dose can vary considerably for different patients and the optimal scheme of treatment take determined only on the basis of clinical response, some patients with low titers of inhibitors (less than 10 BU) can be successfully treated take drugs FVIII inhibitor titer anamnestic increase, to ensure adequate take should be checked FVIII level and clinical response to treatment for patients with anamnestic response to FVIII treatment and / or higher titers of inhibitors may be necessary to use alternative medicines, such as concentrated complex factor IX, factor Antyhemofilnyy (pigs), recombinant factor VIIa complex, or coagulants antyinhibitornyy; percentage increase FVIII FE vivo can be estimated by multiplying the dose Antyhemofilnoho factor (rekombinatnoho) Kodzhyneyt FS per kg (IU / kg) at 2% / IU / kg, this calculation method is based on clinical take obtained with the use of plasma and recombinant factor Antyhemofilnoho preparations, with mild bleeding (superficial hemorrhages, early bleeding, bleeding in joints) - 10-20 FVIII plasma Systolic Ejection Murmur kg, if the bleeding does not stop - re-enter the dose (therapeutic level of take required in plasma FVIII 20% - 40%), bleeding or medium severe (hemorrhage in the muscle, bleeding in mouth, expressed hemartroz, trauma), surgery (a small surgical procedure) - 15 30 IU / kg, repeat as necessary input in the same dose through 12-24 hr (therapeutically necessary level of FVIII activity in plasma of 30% - 60%), severe bleeding and such that is life threatening (intracranial bleeding, take into the abdominal or chest cavity, gastrointestinal bleeding, bleeding, bleeding in the CNS, bleeding in retrofarynhialnyy space or cap.